Background: Glioblastoma multiform (GBM) is a devastating brain tumor with maximum surgical resection, radiotherapy plus concomitant and adjuvant temozolomide (TMZ) as the standard treatment. Diverse clinicopathological and molecular features are major obstacles to accurate predict survival and evaluate the efficacy of chemotherapy or radiotherapy. Reliable prognostic biomarkers are urgently needed for postoperative GBM patients.
Background
Glioblastoma multiforme (GBM) is regarded as the most common malignant brain tumor in adults, accounting for 47 .1% of all malignant brain tumors [1] , and the median survival time of untreated patients with GBM is only 3 months [2] . For malignant brain tumors, according to the Central Brain Tumor Registry of the United States (CBTRUS), the incidence rate of GBM in the United States is extremely high (3.20/100,000 population) and increases with age [1] . Maximal surgical resection, is considered as the first-line treatment for GBM patients relieving clinical symptoms, extending survival time and providing tissue to pathological diagnosis [3] . A large-scale randomized phase III trial, initiated by the European Organization for Research and Treatment of Cancer and National Cancer Institute of Canada Clinical Trials Group, found that the 2-year survival rate of GBM patients was improved to 26.5% by radiotherapy plus temozolomide from 10.4% by radiotherapy alone [4] . Since then, the standard therapeutic strategy for glioblastoma patients has become the multimodal treatment with radiotherapy and chemotherapy after surgery. Therefore, prediction of response to chemotherapy drugs or radiation and prediction of prognosis are crucial for post-surgical GBM patients.
In 1993, the Radiation Therapy Oncology GroupRecursive Partitioning Analysis (RTOG-RPA) classification system was developed for high-grade glioma patients with similar survival times [5] and validated its prognostic significance in GBM patients [6] [7] [8] . However, all the stratification variables of RTOG-RPA risk classification are clinical factors including age, tumor size and location, treatment, karnofsky performance score (KPS), cytologic, histologic composition and so on. Due to the intra-and inter-individual heterogeneity, the RTOG-RPA classification could not satisfactorily predict the survival and tumor response to therapy of each individual [9] . Therefore, molecular markers are becoming more useful in the field of prognosis prediction [10] . Currently, GBM related researches from genomics, epigenomics and transcriptomics level have led to unprecedented discoveries of potential prognostic and predictive indicators [11] . Genomic analysis suggests survival-related genomic abnormalities in GBM patients, such as epidermal growth factor receptor (EGFR) amplification [12, 13] and isocitrate dehydrogenase 1/2 (IDH1/2) mutations [14, 15] , have prognostic value. Some studies show that high expression of EGFR indicated poor prognosis [16] , and other research find the IDH mutations are associated with improved survival [17] . From the epigenetic level, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been demonstrated that it is associated with improved progression-free and overall survival in GBM patients treated with alkylating agents [18] . However, genomic prognostic classification of GBM is not yet clinically feasible, and the mechanism of how these multiple genomic alterations affect clinical prognosis is not clear [19] . As far as the transcriptomics level is concerned, studies mostly focus on mRNA or protein coding gene (PCG) and long noncoding gene (lncRNA) because of their role as gene expression regulators, tumor suppressors and oncogenes. Using PCGs or lncRNAs, numerous studies have constructed transcriptome prognosis models for GBM survival prediction. Zhu et al. screened out an effective prediction system composed of 63 signature genes for glioblastoma prognosis [20] . Marko et al. identified a 43-gene "fingerprint" from a population of 1478 differential expressed genes (P < 0.01) that distinguished GBM survival phenotypes [21] . Anindya Dutta et al. in a global analysis identified 584 lncRNAs correlated with a poor prognosis and 282 lncRNAs associated with better survival outcomes in GBM patients [22] . Above researches verify PCGs and lncRNAs can be prognostic biomarkers of GBM. However, these studies found too many prognostic genes to provide a clinically feasible transcriptome signature with a small number of genes to predict the survival of GBM patients. Therefore, we focus our attention on find out a molecular signature which contains few prognostic genes and could more accurately predict the outcomes of postoperative GBM patients and guide the tailored therapy.
In the present study, we sought to explore the role of multi-transcriptome signature in the prognosis of GBM patients after surgery. We analyzed 233 postoperative GBM patients with the expression profiles of mRNAs and lncRNAs and screened out genes significantly associated with survival. Through further bioinformatics analysis, we aimed at constructing a prognostic transcriptome signature to divide patients into different risk groups, thereby assessing the survival and treatment response for GBM patients after surgical resection.
Methods

Glioblastoma multiforme datasets
We downloaded the normalized TCGA level 3 mRNA expression data and corresponding clinical information of GBM patients (n = 153) from the UCSC Xena (https :// gdc.xenah ubs.net/downl oad/TCGA-GBM/Xena_Matri ces/TCGA-GBM.htseq _fpkm.tsv.gz). LncRNA expression data of the corresponding GBM patients was obtained from the TANRIC database (https ://ibl.mdand erson .org/tanri c/_desig n/basic /downl oad.html) [23] . Another part GBM expression data (GSE7696, n = 80) and corresponding clinical data was obtained from the publicly available GEO database (https ://www.ncbi.nlm. [25] . For the remaining genes with missing expression value in less than 30% of samples or patients, we used the mean of the corresponding genes expression values by R program to replace the missing expression values. We used the expression value on a log2 scale in the subsequent analysis. A total of 233 glioblastoma patients concurrent with gene expression profiles and clinical information were utilized in our study. Of these, all GBM patients were postoperative, then treated with radiotherapy or chemotherapy. The 153 GBM patients from TCGA database were randomly assigned to a training set (n = 76) or a testing set (n = 77) using the 'sample' function [26] from R library and the 80 patients from GSE7696 were served as an independent validation set. Table 1 described the clinical characteristics and therapy information of the TCGA and GEO cohort respectively.
Construction of the prognostic PCG-lncRNA signature in the training dataset
The relationship between the expression of PCG or lncRNA and patients' overall survival (OS) was analyzed by univariate Cox proportional hazards regression analysis in the training dataset. Genes were selected if P value < 0.05. Before constructing a risk prediction model, the random survival forests-variable hunting (RSFVH) algorithm was performed to filter genes. In the random survival forest supervised classification algorithm, an iteration procedure was implemented to narrow down the gene set, and each iteration step discarded the 1/4 least important PCGs or lncRNAs. One thousand trees were grown at each step, and the square root of the number of input nodes at each step was set to the size of randomly chosen PCGs or lncRNAs at each node of single classification tree. Because the number of good-prognostic and poor-prognostic patients were not equal, the class weights were adjusted accordingly. The generalization error was estimated on the outof-bag samples. Finally, six PCGs and six lncRNAs were selected [27] [28] [29] . Risk prediction score model was developed by these selected genes, weighted by their estimated regression coefficients as follows [30] .
where N is the number of prognostic lncRNAs or PCGs, Exp i is the expression value of lncRNAs or PCGs, and Coe i is the estimated regression coefficient of PCGs or lncRNAs in the univariate Cox regression analysis. Then each patient obtained 4095 risk scores because six PCGs and six lncRNAs could form 2 12 − 1 = 4095 combinations or signatures. The receiver operating characteristic (ROC) curve was used to compare the sensitivity and specificity of the 4095 signatures in the training dataset. Area under the curve (AUC) were calculated from the ROC curve. By comparing the AUC values, we selected the prognostic PCG-lncRNA signature in the training set.
Statistical analysis and bioinformatics analysis
With the median risk score in the training dataset as the cutoff value, the GBM patients in training or test set were divided into high-risk or low-risk group [31] . In GSE7696, X-tile software was used to select cutoff value for risk grouping [32] . The Kaplan-Meier analysis and the log-rank test were used to assess and compare survival differences between the low-risk and high-risk groups. ROC analysis was tested to compare the survival predictive power. Furthermore, to test whether the [33] .
Results
Characteristics of study subjects
In this study, the GBM patients after surgical resection and their expression profiles were used as the main subjects. After screened the data downloaded from the TCGA, TANRIC and GEO database, we identified 233 eligible patients diagnosed with GBM concurrently including PCG and lncRNA expression profiles and corresponding clinical data. All these GBM patients received surgical treatment and the median age of the enrolled patients was 60 years (21-89 years). Simultaneously, we obtained a total of 14,607 PCGs and 6613 lncRNAs from the 233 GBM patients.
Identification of the prognostic PCG-lncRNA signature in the training dataset
Firstly, in order to find the survival-related genes in training set, univariate cox proportional hazards regression analysis was performed and identified a 707-genes set including 437 PCGs and 270 lncRNAs in the training dataset which were significantly correlated with OS (P < 0.05, Additional file 1: Table S1 ). The volcano plot displayed the 707 genes with statistical differences as the blue dots in Fig. 1a . Secondly, to further narrow down the number of prognostic PCGs or lncRNAs, we analyzed the above 707 survival related genes by random survival forest algorithm and got six PCGs (EIF2AK3, EPRS, GALE, GUCY2C, MTHFD2, RNF212) and six lncRNAs (LINC00618, LINC02015, AC068888.1, CERNA1, CTD-2140B24.6, ZMIZ1-AS1) significantly associated to OS of GBM patients according to the permutation important score in every step: Discard 1/4 less important PCGs and lncRNAs at each step based on estimating the important score for each PCG or lncRNA using the out-bag samples by pemutation testing (Fig. 1b-d) .
Thirdly, putting the six lncRNAs and six PCGs into the risk score model constructed in methods, we obtained a total of 2 12 − 1 = 4095 models or signatures that included different gene numbers from 1 to 12, indicating that PCGs and lncRNAs alone or the combination of PCGs and lncRNAs were included in these 4095 models. To screen out a signature with biggest predictive power, we performed ROC analysis 4095 times using the survival status as label and signature risk scores of GBM patients as variable in the training dataset by pROC R packages. After compared the AUC values of all these 4095 signatures (Additional file 2: Table S2 ), we identified the max AUC value was 0.78 ( Fig. 1e, f ) from the PCG-lncRNA signature comprising six PCGs (EIF2AK3, EPRS, GALE, GUCY2C, MTHFD2, RNF212) and five lncRNAs (LINC00618, LINC02015, AC068888.1, CERNA1 and CTD-2140B24.6).
The risk score model was constructed as follows: Risk
expression) + (− 0.74 × CTD-2140B24.6 expression). Among them, the coefficients for PCGs (EIF2AK3, EPRS, MTHFD2 and RNF212) and lncRNAs (LINC02015, CTD-2140B24.6) are negative, and the coefficients for PCGs (GALE, and GUCY2C) and lncRNAs (LINC00618, AC068888.1 and CERNA1) are positive ( Table 2) .
Validation the survival prediction of the PCG-lncRNA signature in the three dataset
The risk score model constructed by the PCG-lncRNA signature in the training dataset gave each patient a risk score. Patients from the training dataset were divided into high-risk group (n = 38) and low-risk group (n = 38) when the median risk score was used as the cutoff point. Kaplan-Meier survival analysis was performed to compare the overall survival of two risk groups of patients. As we can see in Fig. 2a , the OS rates were significantly different in patients from the two groups. Compared with those in the low-risk group, patients in the high-risk group had a shorter survival time (median survival: 7.47 months vs. 18.27 months, log-rank test P < 0.001) and lower OS rate (5% vs. 50%, log-rank test P < 0.001, Fig. 2a ). The important score of selected PCGs or lncRNAs which were calculated by random survival forest analysis. e The 11 genes with largest AUC (k = 1, 2, … 12, k represents the gene number in the corresponding signature) were shown in the plot. f After calculating the AUC of 4095 signatures, the prognostic PCG-lncRNA signature with biggest predictive power (AUC = 0.78) was screen out To validate the predictive power of the signature, we calculated the PCG-lncRNA signature-based risk scores of 77 patients in the test dataset. When the same median cutoff point obtained from the training dataset was used, patients from the test dataset were also separated into low-risk and high-risk groups (median survival: 11.4 months vs. 16.8 months, log-rank test P = 0.001, Fig. 2b ). The OS rate of patients in the high-risk group was about 19.4% vs. 53.7% in the low-risk group (Fig. 2b ). In the independent set, Kaplan-Meier analysis found the PCG-lncRNA signature classified patients into different two risk groups (median survival: 8.93 months vs. 16.22 months, log-rank test P = 0.007, Fig. 2c ). Moreover, shorter survival time was noted in GBM patients with higher risk-scores in the training, test and independent datasets and P-values were calculated by the rank-sum test ( Fig. 2d-f ).
The PCG-lncRNA signature is an independent prognostic factor from other clinical variables and molecular features After demonstrating the survival predictive power of PCG-lncRNA signature, we need to clarify whether the PCG-lncRNA signature was an independent prognostic factor since numerous factors affect GBM prognosis. Thus we performed univariable cox analysis and multivariable Cox regression analysis in which covariates included the PCG-lncRNA signature-based risk score and clinical features (Table 3) . Multivariable Cox regression analysis showed that the PCG-lncRNA risk score remained to be significantly associated with overall survival when adjusted other clinical features including sex, age and Karnofsky performance score in the training and the test dataset (High-risk group vs. Low-risk group, HR = 5.94, 95% CI 2.66-13.25, P < 0.001; HR = 2.89, 95% CI 1.35-6.20, P = 0.01). The independent dataset showed the independent predictive power of PCG-lncRNA signature (HR = 2.17, 95% CI 1.16-4.07, P = 0.02) when adjusted other clinical features including sex, age.
Subsequently, examining the clinical data of these 153 TCGA GBM patients after surgical resection, we obtained 73 samples with known status of MGMT promoter and 80 samples with known status of IDH1 mutation (both known were 70 samples). Multivariable Cox regression analysis showed that the PCG-lncRNA risk score was significantly associated with overall survival when adjusted the molecular features including MGMT promoter and IDH1 mutation in the 70 TCGA GBM patients (High-risk group vs. Low-risk group, HR = 3.71, 95% CI 1.80-7.62, P < 0.001).
Comparing the survival predictive power of the signature with that of age, IDH1 mutation and MGMT promoter methylation status
To compare the survival predictive power of the PCGlncRNA signature with the reported prognostic factors, such as age, IDH1 mutation and MGMT promoter methylation status, we performed a series of ROC analyses considering that a larger AUC usually represented a better predictive power [34, 35] .
In the training dataset (n = 76), the AUC of the PCG-lncRNA signature was bigger than that of age, indicating a better predictive power in GBM prognosis (Signature-AUC = 0.78 vs. Age-AUC = 0.56, Fig. 3a) . The same result can be seen in the test dataset (Fig. 3g) .
In addition, Kaplan-Meier survival analysis was performed in the 73 samples with known status of MGMT promoter and 80 samples with known status of IDH1 mutation to compare the risk grouping ability of the PCG-lncRNA signature with that of MGMT and IDH1 mutation. Using the same median cutoff point obtained from the training dataset, the PCG-lncRNA signature showed a robust efficiency to separate corresponding patients into two risk groups with different survival time (P < 0.001, Fig. 3e, h) , however, the MGMT and IDH1/2 did not group well (P > 0.05, Fig. 3f, i) .
Stratification analysis of TMZ-chemoradiation treatment
The relationship between the PCG-lncRNA signature with a series of clinicopathological parameters in the entire TCGA dataset (n = 153) was analyzed. As can be seen in Table 4 , there was an association between PCGlncRNA signature and TMZ-chemoradiation (Chi square test, P < 0.05, Table 4 ). Obviously, TMZ-chemoradiation ) and TimeROC analysis in the entire set (c). TimeROC analysis for comparison of the survival predictive power of the PCG-lncRNA signature with that of MGMT promoter methylation status (d) and IDH1 mutation (g). Kaplan-Meier survival curves found the PCG-lncRNA signature (e, h) could classify patients with known MGMT promoter (f) and IDH1 mutation status (i) into high-and low-risk groups by the PCG-lncRNA signature in each corresponding TCGA dataset. Kaplan-Meier survival curves found the MGMT and IDH1/2 could not group patients into high-and low-risk groups treatment could stratify post-operative GBM patients into treated stratum and untreated stratum. Data stratification analysis using the PCG-lncRNA signature risk score further divided the patients into four groups: high-risk and treated, high-risk and untreated, low-risk and treated, low-risk and untreated. The Kaplan-Meier test was performed and Kaplan-Meier curves showed in Fig. 4 . The log-rank test showed that TMZ-chemoradiation treated patients in high-risk group with shorter survival than TMZ-chemoradiation treated patients in low-risk group (n = 62, P < 0.001, Fig. 4a ). The TMZchemoradiation untreated patients were also divided into a high-risk group with lower OS and a low-risk group with higher OS (n = 83, P = 0.005, Fig. 4b ), indicating the stratification power of the PCG-lncRNA signature in TMZ-chemoradiation GBM patients.
In consistence with the findings in TCGA described above, for GSE7686 dataset, the PCG-lncRNA signature could stratify the TMZ-chemoradiation treated or untreated patients into a high-risk group and a low-risk group with different survival (log-rank test P = 0.03, Fig. 4c , log-rank test P = 0.13, Fig. 4d ).
Functional characterization of the prognostic genes in the PCG-lncRNA signature
Co-expression network analysis was carried out in the entire TCGA dataset visualized by Cytoscape [36] and we found 2328 protein-coding genes co-expressed with the prognostic 6 PCGs and 5 lncRNAs in the signature (Absolute value of the Pearson correlation coefficient > 0.40, P < 0.05, Additional file 3: Table S3 ). Then we performed pathway analysis by SubpathwayMiner (see method) and found these co-expressed genes were enriched in 90 different pathways (P < 0.05, Additional file 4: Table S4 ). The gene set were significantly associated with different cancer types such as non-small cell lung cancer, prostate cancer, thyroid cancer, bladder cancer and glioma (P < 0.05, Fig. 5a ). And these results suggested that the 11 genes, via the co-expressed genes, could exert their regulatory roles by implicating in regulating downstream pathways such as JAK-STAT signaling pathway, MAPK signaling pathway, WNT signaling pathway, Cell cycle, TGF-beta signaling pathway and p53 signaling pathway (P < 0.05, Fig. 5b, c) .
Discussion
Glioblastoma multiforme (GBM) is a heterogeneous disease characterized by poor prognosis. In order to extend the survival time of patients with GBM, in recent year, adjuvant and concomitant temozolomide with radiation are widely used. Despite advances in treatment such as radiation and chemotherapy, the prognosis and therapy response for post-surgical GBM patients with similar clinical risk factors varied tremendously. Considering the molecular heterogeneity of GBM, in this study, we identified a prognostic molecular indicator comprising five long non-coding RNAs and six protein coding genes, and confirmed the survival prediction power of the PCGlncRNA signature in postoperative GBM patients. Molecular markers are of great significance to disease diagnosis, treatment decision and prognosis assessment. With regard to the prognostic molecular characterization of GBM, the 2016 World Health Organization (WHO), for the first time, used the isocitrate dehydrogenase (IDH) gene mutation status as the classification molecular parameter to separate the GBM into three groups: GBM IDH-wild type, GBM IDH-mutant, and GBM NOS [37] , with different prognosis [38] . In the past decade, GBM prognostic studies focused on mRNA or PCG as a result of the development of sequence technology and The Cancer Genome Atlas (TCGA) database. Chen et al. selected a gene expression signature score (GGESS) by incorporating ten glycolytic genes significantly correlated with patient survival and verified that the PCG signature
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